Benzinga | Nov 5, 2021 09:48AM EDT

Oppenheimer Maintains Perform on Nektar Therapeutics, Lowers Price Target to $21

Oppenheimer maintains Nektar Therapeutics (NASDAQ:NKTR) with a Perform and lowers the price target from $25 to $21.